Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death

Erasca shares plunged as much as 55% after the company said one patient withdrew from its clinical trial and later died following severe treatment-related side effects. The event raises significant safety concerns around the cancer-drug candidate and is likely to pressure investor confidence in the program and the stock.

Analysis

Erasca shares plunged as much as 55% after the company said one patient withdrew from its clinical trial and later died following severe treatment-related side effects. The event raises significant safety concerns around the cancer-drug candidate and is likely to pressure investor confidence in the program and the stock.